Peripheral Neuropathy Treatment Market Analysis & Forecast: 2026-2033
The peripheral neuropathy treatment market was valued at USD 2,091.7 Mn in 2026 and is forecast to reach a value of USD 2,715.9 Mn by 2033 at a CAGR of 3.8% between 2026 and 2033.
Peripheral neuropathy, a result of damage to the nerves located outside of the brain and spinal cord (peripheral nerves), often causes weakness, numbness and pain, usually in the hands and feet. It can also affect other areas and body functions including digestion, urination and circulation.
|
Current Event |
Description and its Impact |
|
Aging Global Population and Rising Diabetes Prevalence |
|
|
Regulatory Landscape Evolution and Drug Approval Processes |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of treatment, the pharmacological therapies segment is expected to lead the market with 62.4% share in 2026. Pharmacological therapies continue to be the foundation of peripheral neuropathy treatment. Pain relievers, anti-seizure medications, and antidepressants are generally prescribed, providing symptomatic relief and ease of access. Even though more people are interested in non-drug treatments, drug-based treatments are still the most common due to their efficacy in clinical settings, doctors prefer them, and patients rely on drugs for quick and long-term pain relief.
For instance, in September 2025, researchers at Northeastern University are working on a non-opioid drug therapy for neuropathic pain that will help people rely less on addictive opioids. This new method focuses on peripheral neuropathy and provides safer and more effective pain relief. The study shows promising drug mechanisms that could change how patients are treated and make their lives better.
In terms of indication, the diabetic peripheral neuropathy segment is expected to hold 47.8% share of the market in 2026, due to diabetes epidemic, especially among older people. Obesity, sedentary lifestyles, and poor glycemic control are all on the rise, which damages nerves and makes people want treatment. Since it is so common, it will always be at the top of the market. Pharmaceutical companies focus on treatments for diabetic complications and pain management.
For instance, in May 2025, The FDA provided Abbott's Proclaim XR spinal cord stimulation device its approval to help with pain from nerve damage caused by diabetes. This implantable neurostimulator sends mild electrical pulses to the spine that prevent pain signals from getting to the brain. This helps people with diabetic neuropathy feel better.
In terms of end user, the hospitals segment is projected to account for 57.2% share of the market in 2026, because they have advanced infrastructure, specialized neurologists, and full diagnostic facilities. A significant number of patients, especially those with diabetes and neuropathy caused by chemotherapy, which makes them even more powerful. Hospitals also help with clinical trials and getting new treatments, which shows the importance of providing good neuropathy care around the world.
To learn more about this report, Download Free Sample
North America is expected to dominate the peripheral neuropathy treatment market with 42.7% share in 2026, due to a high number of people with diabetes, cases of neuropathy caused by chemotherapy, an advanced healthcare system, a strong pharmaceutical industry, and good reimbursement policies. All of these things together make sure that new therapies are widely used and keep the region's market leadership.
For instance, in December 2025, The FDA provided Sangamo Therapeutics the Fast Track designation for ST-503, a new treatment for small fiber neuropathy, a type of peripheral neuropathy. This designation, which was created in the United States, accelerated the regulatory review process and shows that the therapy could help people with nerve damage who do not possess enough options for treatment.
Asia Pacific is expected to exhibit the fastest growth, because more people are getting diabetes, the population is getting older, and people in China and India are having health problems related to their lifestyles. The region is the fastest-growing market in the world due to more healthcare facilities, more people knowing about them, and rising investment into neurology and pain management.
For instance, in March 2025, PGI Chandigarh has introduced to India an AI-powered device that will change the way neuropathic pain is diagnosed. It is unable to directly treat peripheral neuropathy, but it makes hospital care better by making it easier to find it faster and more accurately. This new idea helps doctors take better care of patients and makes it easier to make diagnoses in clinical neurology all over the country.
The U.S. peripheral neuropathy treatment market will be extremely productive in 2026 as rising prevalence of diabetes, more people are getting neuropathy from chemotherapy, and the population is getting older. The U.S. is the largest regional market in the world because it has advanced healthcare infrastructure, strong pharmaceutical research and development, and policies that make it easier for people to get new treatments.
For instance, in January 2026, the FDA has given Lexicon Pharmaceuticals approval to move Pilavapadin into Phase 3 trials for diabetic peripheral neuropathic pain in the US. This experimental oral treatment aims to give diabetic patients a way to manage neuropathic pain without using opioids, which is a big medical need that has not been met in hospitals.
As diabetes is rising in demand, the population ages, and lifestyle-related health problems become more common, the need for peripheral neuropathy treatment in Australia rises in 2026. Australia is a major player in the fast-growing Asia-Pacific market because of its expanding healthcare infrastructure, government support for neurological research, and growing awareness of pain management therapies.
For instance, in February 2026, Grünenthal received the exclusive rights to market Qutenza in Australia. This topical capsaicin 8% patch is used to treat peripheral neuropathic pain. The deal with Clinect makes this therapy more available in Australia, giving hospitals and clinics more options for treating neuropathy symptoms and improving patient care with new ways to relieve pain.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,091.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.8% | 2033 Value Projection: | USD 2,715.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy’s Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Diabetic peripheral neuropathy, one of the most common complications of diabetes, has become more common as the number of people with diabetes has risen around the world. As rising volume of high blood sugar levels for a long time damages their nerves, the need for effective treatments grows. This trend greatly increases the peripheral neuropathy treatment market demand, as healthcare providers and drug companies work hard to develop advanced solutions to treat pain, improve mobility, and make patients' lives better.
Chemotherapy and other cancer treatments often cause peripheral neuropathy, which can have severe side effects. As cancer rates rise around the world, more people are taking neurotoxic drugs, which is increasing needs for supportive care and specialized therapies. This trend is increasing the peripheral neuropathy treatment market share as drug companies and medical device companies are coming up with new ways to reduce nerve damage caused by chemotherapy. This makes patients better and reducing treatment discontinuation rates
The introduction of affordable generics in the peripheral neuropathy treatment market forecast opens up a lot of doors, especially in developing countries. Generics lower the cost of treatment, making it possible for more people with diabetic neuropathy and nerve damage caused by chemotherapy to get the care they need. Generics make it easier for more people to use them, which helps meet the growing demand for healthcare in Asia-Pacific and Latin America. Pharmaceutical companies benefit from growth based on volume, while governments support generic drugs to make healthcare more affordable and less burdensome.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
